Healthcare Industry News: Esperion
News Release - July 12, 2007
Resverlogix Corp.: Dr. Roger Newton, Co-Discoverer of Lipitor(R), Commences his Board of Directors PositionCALGARY, ALBERTA--(Healthcare Sales & Marketing Network)--Jul 12, 2007 -- Resverlogix Corp. ("Resverlogix") (Toronto:RVX.TO ) is pleased to announce today that Dr. Roger Newton has joined the Board of Directors effective immediately.
"This is a fascinating time to be joining Resverlogix's Board of Directors as momentum is gaining for the NexVas(TM) Plaque Regression technology," stated Dr. Newton. "The excitement for me comes from knowing that by raising ApoA-l and functional HDL we can regress atherosclerosis. Thus the opportunity to be first in an entire new class of drugs for the treatment of cardiovascular disease due to atherosclerosis is very appealing."
"Dr. Newton's exceptional track record of creating highly successful endeavors in the pharmaceutical industry is well received by both Resverlogix's Board and management," said Donald McCaffrey, President and CEO of Resverlogix. "Dr. Newton is highly discerning with the advisory roles that he accepts, hence joining Resverlogix speaks to the unprecedented opportunity to address important diseases that is embedded in our NexVas technology. His expertise and guidance will help take RVX 208, our lead drug candidate to new levels of development."
Dr. Newton has 25 years experience in the pharmaceutical and life sciences industries. He is the former Senior Vice President of Pfizer Global Research and Development and Director of Esperion Therapeutics, a Pfizer Inc. company. He was Co-Founder, President and CEO of Esperion Therapeutics, Inc., a biopharmaceutical company founded in July 1998. Esperion was acquired by Pfizer in February 2004 for $1.3 billion. Prior to co-founding Esperion, Dr. Newton was with Warner-Lambert/Parke-Davis (now Pfizer) from 1981-1998. As a distinguished scientist and chairman of the Atherosclerosis Drug Discovery Team, he co-discovered and was product champion of what is now the most prescribed cholesterol reducing drug in the world, atorvastatin (LipitorŪ).
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-l. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (Toronto:RVX.TO ). For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.
The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.